LTZ Therapeutics raises $17M for Pre-Series A Financing, a Palo Alto-based biotech company and Shenzhen, China-based company called.
K2 Venture Partners was the leader of the round. Tigermed and Qiming Venture Partners also participated.
The company plans to use the funds for its three-pronged platform development, to establish its initial pipeline, and to further develop the operations team.
Co-founded by seasoned drug developers Robert Li Ph.D, Martin Treder Ph.D. and Jianhui Zhou Ph.D., LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. It is committed to the development of immunotherapies capable of overcoming resistance and increasing anti-tumor immune response based on emerging biology and reverse translational research.